Flat corneas produce unpredictable visual outcomes after PRK

Article

Flat, steep corneas with keratometry values of less than 35 D do not have a predictive effect on the risk of visual acuity loss after myopic photorefractive keratectomy (PRK), claims a paper in the Journal of Refractive Surgery.

Flat, steep corneas with keratometry values of less than 35 D do not have a predictive effect on the risk of visual acuity loss after myopic photorefractive keratectomy (PRK), claims a paper in the Journal of Refractive Surgery.

Dr David Varssano et al., Tel-Aviv Medical Centre, Tel-Aviv, Israel, retrospectively analysed the visual acuity of 5410 eyes that underwent PRK from January 2006 to November 2010. All patients were assessed for the effect of postoperative corneal curvatures on visual outcomes. The main outcome measures were postoperative corrected distance visual acuity (CDVA) and loss of CDVA.

A worse postoperative CDVA was observed in corneas with a flat meridian of less than 35 D and those with a steep meridian of less than 35 D. The worst preoperative CDVA presented in the flatter curvatures in all comparisons conducted for the study. This indicates that calculated meridian curvature had no effect on CDVA loss.

Overall, the team discovered that postoperative corneal keratometry values, especially flat and steep meridians, of less than 35 D did not have a predictive effect on the risk of losing visual acuity after myopic PRK.

For the full abstract please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.